Shares of bluebird bio, Inc. (NASDAQ:BLUE – Get Rating) have earned a consensus recommendation of “Hold” from the eighteen analysts that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.31.
Several equities research analysts have issued reports on the company. StockNews.com assumed coverage on bluebird bio in a report on Thursday, March 31st. They set a “sell” rating on the stock. Barclays lowered their price target on bluebird bio from $4.00 to $3.00 in a report on Tuesday, May 10th. Cowen downgraded bluebird bio from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 6th. SVB Leerink lowered their price target on bluebird bio from $10.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, April 6th. Finally, Morgan Stanley lowered their price target on bluebird bio from $6.00 to $5.00 and set an “underweight” rating for the company in a report on Monday, March 7th.
bluebird bio stock opened at $3.39 on Tuesday. The stock’s 50 day moving average price is $4.40 and its 200 day moving average price is $7.72. The firm has a market capitalization of $242.22 million, a PE ratio of -0.32 and a beta of 1.63. bluebird bio has a one year low of $3.11 and a one year high of $35.59.
A number of hedge funds have recently modified their holdings of BLUE. US Bancorp DE increased its position in bluebird bio by 82.9% in the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 3,847 shares during the last quarter. Raymond James & Associates acquired a new position in bluebird bio in the 1st quarter worth about $50,000. Penserra Capital Management LLC acquired a new position in bluebird bio in the 1st quarter worth about $53,000. Bank of Montreal Can acquired a new position in bluebird bio in the 1st quarter worth about $58,000. Finally, Sanders Morris Harris LLC bought a new stake in shares of bluebird bio during the 1st quarter worth about $62,000. 96.38% of the stock is currently owned by institutional investors.
bluebird bio Company Profile (Get Rating)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- Option Care Health Stock is Making a Healthy Pullback
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.